Sign in

    John Boyle • William Blair & Company

    John Boyle, Ph.D., is a Senior Analyst specializing in biotechnology equity research at William Blair & Company, with a focus on neuroinflammation and therapeutic development in neurodegenerative and immunology-related diseases. He covers companies such as AbbVie and frequently collaborates on industry reports that track M&A activity and trends in venture investment among neurology and biotech sector leaders, delivering actionable investment insights for institutional clients. Boyle joined William Blair after earning his doctoral degree, has built his career as a key contributor to the firm's healthcare research, and regularly partners with other senior analysts recognized for their sector expertise. He is a registered FINRA representative and holds the Series 7 and Series 63 securities licenses.

    John Boyle's questions to Neumora Therapeutics Inc (NMRA) leadership

    John Boyle's questions to Neumora Therapeutics Inc (NMRA) leadership • Q1 2025

    Question

    John Boyle of William Blair asked about the potential timing for a decision to increase enrollment size in the KOASTAL-2 and KOASTAL-3 studies and what blinded data would influence such a decision.

    Answer

    Daljit Aurora, Chief Operating and Development Officer, responded that the studies have built-in flexibility to increase enrollment by 25% above the 332-patient base. He confirmed that while the trials are progressing, a final decision on increasing the enrollment size has not yet been made and will be communicated at an appropriate time.

    Ask Fintool Equity Research AI

    John Boyle's questions to Vistagen Therapeutics Inc (VTGN) leadership

    John Boyle's questions to Vistagen Therapeutics Inc (VTGN) leadership • Q3 2025

    Question

    John Boyle from William Blair asked about the development path for AV-101 in neuropathic pain, the rationale for clinician-administered dosing in PALISADE-3 and 4, and the interplay between the SUDS and CGI-I endpoints.

    Answer

    CEO Shawn Singh explained that AV-101 is a candidate for partnering, with confidence in its potential driven by preclinical models. COO Joshua Prince stated that clinician administration in the PALISADE trials aims to reduce variability and ensure consistent dosing, which is not expected to impact the label since the open-label portion involves self-administration. Singh clarified that the SUDS score is the primary endpoint, while the CGI-I provides important context on clinical meaningfulness at an individual level.

    Ask Fintool Equity Research AI